Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 879-884

  Ye, Qi Fa ^a   Zhang, Yi Chuan ^a,b   Peng, Xiao Qing ^b   Long, Zhi ^b   Ming, Ying Zi ^a   He, Le Ye ^b  

^a BEIJING HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Bax; Bcl 2; Notch signaling; Prostate cancer; Small interfering RNA

Indexed keywords

DOCETAXEL; NOTCH1 RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MOLECULAR BIOLOGY; NUCLEOTIDE SEQUENCE; UPREGULATION;

EID: 84863131344     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.572     Document Type: Article

References (34)

1. American Cancer Society: Cancer Facts and Figures 2011. American Cancer Society, Atlanta, 2011.
2. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339: 1036-1042, 1998.
3. Mohler J, Bahnson RR, Boston B, et al: NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8: 162-200, 2010.
4. Ploussard G, Terry S, Maille P, et al: Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 70: 9253-9264, 2010.
5. Petrylak DP, Tangen CM, Hussain MHA, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 351: 1513-1520, 2004.
6. Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 284: 770-776, 1999.
7. Kopan R and Ilagan MX: The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 216-233, 2009.
8. Miele L: Notch signaling. Clin Cancer Res 12: 1074-1079, 2006.
9. Miele L, Golde T and Osborne B: Notch signaling in cancer. Curr Mol Med 6: 905-918, 2006.
10. Leong KG and Gao WQ: The Notch pathway in prostate development and cancer. Differentiation 76: 699-716, 2008.
11. Villaronga MA, Bevan CL and Belandia B: Notch Signaling: a potential therapeutic target in prostate cancer. Curr Cancer Drug Tar 8: 566-580, 2008.
12. Shou JY, Ross S, Koeppen H, de Sauvage FJ and Gao WQ: Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 61: 7291-7297, 2001.
13. + channel activity in human prostate cancer cells: independent modulation of in vitro motility. Prostate Cancer Prostatic Dis 9: 399-406, 2006.
14. Bin Hafeez B, Adhami VM, Asim M, et al: Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res 15: 452-459, 2009.
15. Wang ZW, Li Y, Banerjee S, et al: Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappa B signaling pathways. J Cell Biochem 109: 726-736, 2010.
16. Bushman W, Gipp J, Gu GY, Crylen C and Kasper S: Hedgehog pathway activity in the LADY prostate tumor model. Mol Cancer 6: 19, 2007.
17. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
18. Reagan-Shaw S, Nihal M, Ahsan H, Mukhtar H and Ahmad N: Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. Prostate 68: 1624-1634, 2008.
19. Dotto GP: Notch tumor suppressor function. Oncogene 27: 5115-5123, 2008.
20. Wang M, Xue L, Cao Q, et al: Expression of Notch1, Jagged1 and beta-catenin and their clinicopathological significance in hepatocellular carcinoma. Neoplasma 56: 533-541, 2009.
21. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA and Chen H: Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 281: 39819-39830, 2006.
22. Zheng Q, Qin H, Zhang H, et al: Notch signaling inhibits growth of the human lung adenocarcinoma cell line A549. Oncol Rep 17: 847-852, 2007.
23. Miyamoto Y, Maitra A, Ghosh B, et al: Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3: 565-576, 2003.
24. Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML and Artavanis-Tsakonas S: Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci USA 92: 6414-6418, 1995.
25. Rae FK, Stephenson SA, Nicol DL and Clements JA: Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer 88: 726-732, 2000.
26. Purow BW, Haque RM, Noel MW, et al: Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 65: 2353-2363, 2005.
27. Hopfer O, Zwahlen D, Fey MF and Aebi S: The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 93: 709-718, 2005.
28. Reedijk M, Odorcic S, Chang L, et al: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530-8537, 2005.
29. Zang SL, Chen F, Dai JJ, et al: RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer. Oncol Rep 23: 893-899, 2010.
30. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS and Gabrilovich DI: Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 111: 2220-2229, 2008.
31. McGrogan BT, Gilmartin B, Camey DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785: 96-132, 2008.
32. Rasul S, Balasubramanian R, Filipovic A, Slade MJ, Yague E and Coombes RC: Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer 100: 1879-1888, 2009.
33. Chun E and Lee KY: Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 315: 771-779, 2004.
34. Yoshino T, Shiina H, Urakami S, et al: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12: 6116-6124, 2006.